The case for & against
Bull & Bear analysis
Zoetis Inc. (NYSE: ZTS) is the leading global animal health company specializing in developing and manufacturing veterinary vaccines and medicines across a diverse range of species, including pets and livestock. The company plays a critical role in the agricultural and companion animal markets, with a strong focus on enhancing animal health and wellness. As a dominant player, Zoetis leverages its robust research and development capabilities to support ongoing product innovation and address market needs, positioning itself effectively within the broader trend of increased spending on pet care and livestock health.
Bull says
- ↑Q2 revenue flat at $2.5B, livestock sales surged 23%.
- ↑Adjusted net income $781M (adj. EPS $1.87) shows resilience.
- ↑High profitability and attractive earnings yield support valuation.
- ↑0.38% dividend yield and robust cash returns shield downside.
- ↑New CFO aims to improve operational efficiency and cost control.
- ↑Strong R&D pipeline and market leadership underpins long-term growth.
Bear says
- ↓U.S. revenue fell 7%, companion product sales dropped 11%.
- ↓Full-year revenue guidance cut to $9.12–9.32B from prior $9.68–9.96B.
- ↓Adjusted EPS forecast reduced to $6.15–6.25 from $6.85–7.00.
- ↓High leverage limits financial flexibility amid rising rates.
- ↓Negative earnings revisions and institutional outflows signal low growth expectations.
- ↓Stock hit 52-week low post-earnings, reflecting weak market sentiment.
Investment themes with ZTS
Companies paying above-average dividends
Companies with strong fundamentals and stability
Drug development driving global healthcare solutions
Products and services for pet owners
Earnings Call · Q4 2023 · Mgmt. Guidance
Transcript signals
Bull points
- Our full-year revenue was near the top end of our guidance range, while our adjusted net income was slightly below our guidance range, primarily due to the impact of foreign exchange, as well as an impairment charge related to a prior acquisition.
- Full-year revenue grew 6% on a reported basis and 7% operationally, with adjusted net income anchoring 7% on both a reported and operational basis.
- Performance in companion animal was led by OA pain mAbs, which posted $321 million in global revenue for the year.
Bear points
- while China represents less than 5% of our global revenues, the ongoing economic weakness there continues to impact our business, and represented a half a percentage point drag on our total company operational revenue growth for the year, entirely in volume.
- while we are not leveraging distribution for our pain mAbs, there's a significant clinic stocking impact in the first few months after launch.
- China represented a 3% drag on our international segment operational revenue growth in the quarter.